Dublin, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The "Continuous Manufacturing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Continuous ...
Continuous manufacturing makes monoclonal antibody production faster, cheaper, and greener, say researchers, who predict that industry adoption of the approach will accelerate in response to ...
More and more drugmakers are giving continuous manufacturing a try, seeing it as the future in small molecule drug production, in part, because the plants for the process are much smaller than those ...
New York, March 10, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Continuous Manufacturing Market : Industry Trends and Global ...
A handful of companies have done pioneering work with continuous manufacturing, the production process that is faster, cheaper and less prone to the kinds of manufacturing mess-ups that worry the FDA.
The pharmaceutical industry has been slow to adopt a business practice that is faster, safer, and more efficient than its current way of operating; that the FDA has been encouraging the industry to ...
Although estimates vary slightly, many industry experts predict continuous manufacturing will, at the least, cut the cost of manufacturing biologics in half. Thus, it will be an attractive option for ...
DIANT is a startup co-founded by Antonio Costa, Ph.D. and Diane Burgess, Ph.D. In 2020, DIANT licensed their core manufacturing technology from UConn and was granted a patent on the technology earlier ...
One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology Framingham, Massachusetts facility will manufacture biologics for the ...
This workshop will discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics, such as enzymes, monoclonal antibodies, and ...
The biopharmaceutical industry has seen substantial growth in recent years, generating novel biotherapeutics and biosimilars at an unprecedented rate. One of the biggest challenges in the industry is ...
Nick Pinchuk, president and CEO of Snap-on (IW 500/271), wields continuous improvement as a weapon, a weapon against the turbulent manufacturing climate, a weapon against the dwindling middle class, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback